Changes in survival and time to progression in metastatic breast cancer (MBC) patients enrolled into clinical trials from 1983 to 2001.

被引：0
|
作者：
Gennari, A
Conte, P
Orlandini, C
Guarneri, V
Rosso, R
Bruzzi, P
机构：
[1] Div Med Oncol, Pisa, Italy
[2] Div Med Oncol, Modena, Italy
[3] NCI, Genoa, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
634
引用
收藏
页码：35S / 35S
页数：1
相关论文
共 50 条
  • [1] Evaluation of overall survival (OS), progression-free survival (PFS), or time to progression (TTP) in systematic review of randomized clinical trials (RCT) in patients with metastatic breast cancer (MBC)
    Mukonje, Terence
    Santana-Davila, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] Contribution of clinical trials to improved clinical outcomes for patients with metastatic breast cancer (MBC).
    Lee, Ji Yun
    Lim, Sung Hee
    Lee, Min-Young
    Kim, Haesu
    Ahn, Jin Seok
    Im, Young-Hyuck
    Park, Yeon Hee
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials
    Criscitiello, Carmen
    Marra, Antonio
    Morganti, Stefania
    Zagami, Paola
    Gandini, Sara
    Esposito, Angela
    Curigliano, Giuseppe
    EUROPEAN JOURNAL OF CANCER, 2021, 157 : 40 - 49
  • [4] The Impacts of Inclusion in Clinical Trials on Outcomes among Patients with Metastatic Breast Cancer (MBC)
    Lee, Ji Yun
    Lim, Sung Hee
    Lee, Min-Young
    Kim, Hae Su
    Ahn, Jin Seok
    Im, Young-Hyuck
    Park, Yeon Hee
    PLOS ONE, 2016, 11 (02):
  • [5] The landscape of patients with metastatic breast cancer enrolled in phase I trials
    Marra
    Criscitiello, C.
    Morganti, S.
    Zagami, P.
    Viale, G.
    Tarantino, P.
    Trapani, D.
    Nicolo, E.
    Repetto, M.
    Ferraro, E.
    D'Amico, P.
    Locatelli, M.
    Esposito, A.
    Curigliano, G.
    ANNALS OF ONCOLOGY, 2020, 31 : S70 - S71
  • [6] Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?
    Watson, Sarah
    Menis, Jessica
    Baldini, Capucine
    Martin-Romano, Patricia
    Michot, Jean-Marie
    Hollebecque, Antoine
    Armand, Jean-Pierre
    Massard, Christophe
    Soria, Jean-Charles
    Postel-Vinay, Sophie
    Paoletti, Xavier
    BRITISH JOURNAL OF CANCER, 2018, 119 (08) : 937 - 939
  • [7] Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?
    Sarah Watson
    Jessica Menis
    Capucine Baldini
    Patricia Martin-Romano
    Jean-Marie Michot
    Antoine Hollebecque
    Jean-Pierre Armand
    Christophe Massard
    Jean-Charles Soria
    Sophie Postel-Vinay
    Xavier Paoletti
    British Journal of Cancer, 2018, 119 : 937 - 939
  • [8] Clinical use of trastuzumab (Hereeptin®) in metastatic breast cancer (MBC) in Germany from 2001 to 2006.
    Dackisch, C.
    Eustermann, H.
    Schoenegg, W.
    Soelling, U.
    Stanch, M.
    Goehler, T.
    Kuehn, W.
    Krieger, G.
    Reichert, D.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S186 - S186
  • [9] Correlation between time to progression and overall survival in patients with metastatic breast cancer
    Sherrill, B.
    Hirst, C.
    Wu, Y.
    Amonkar, M. M.
    Stein, S.
    VALUE IN HEALTH, 2007, 10 (03) : A123 - A124
  • [10] Does participation in clinical trials influence on survival in patients with metastatic breast cancer?
    Kim, T-Y
    Sohn, J. H.
    Kim, S-B
    Yoon, J. H.
    Kim, G. M.
    Lee, K. H.
    Koh, S-J
    Park, Y. H.
    Lee, S. E.
    Chae, Y.
    Lee, K. S.
    Lee, K. E.
    Won, H. S.
    Kim, J. H.
    Jeong, J.
    Park, K. H.
    Cho, E. K.
    Im, Y-H
    Im, S-A
    Jung, K. H.
    CANCER RESEARCH, 2016, 76
12345